Reverted Compounds definition

Reverted Compounds shall have the meaning described in Section 15.2(a).
Sample 1Sample 2Sample 3
Reverted Compounds means (A) all Compounds known as of the effective date of the applicable CDI Cessation Notice and all other molecules within the libraries of CTLA-4 Variants existing on the effective date of the applicable CDI Cessation Notice (provided, however, that all Clinical Candidates which are, as of the effective date of the applicable CDI Cessation Notice, in clinical trials or being Commercialized for Exclusive Indications, shall be excluded from the definition of “Reverted Compounds” for so long as Astellas retains its exclusive license hereunder with respect to such Clinical Candidates for the Exclusive Indications (such Clinical Candidates being the “Excluded Compounds”)), and (B) molecules (other than any Excluded Compounds) in new CLTA-4 Variant libraries created through Shuffling after the effective date of the applicable CDI Cessation Notice (provided, however, that Astellas-Selected New Compounds, as defined below, shall not be “Reverted Compounds” for so long as Astellas retains its exclusive license hereunder with respect to such Clinical Candidates for the Exclusive Indications);
Sample 1
Reverted Compounds means any Collaboration Compounds licensed to Exelixis under Sections 10.4(d)(i) and (ii).
Sample 1

Examples of Reverted Compounds in a sentence

  • Celgene shall have the right to grant sublicenses or licenses, within the scope of the license under Section 8.2(e) above, to Third Parties to Develop, Manufacture or Commercialize Celgene Reverted Compounds and/or Celgene Reverted Products.

  • The Parties agree that decisions regarding the timing and content of Publications shall be subject to the oversight and approval by Mutual Consent of the JSC and neither Party nor its Affiliates shall have the right to make Publications pertaining to Agreement Compounds (other than Agios Reverted Compounds) or Targets except as provided herein.

  • Agios shall have the right to grant sublicenses or licenses, within the scope of the license under Section 8.2(f) above, to Third Parties to Develop, Manufacture or Commercialize Agios Reverted Compounds and/or Agios Reverted Products.

  • Celgene shall be solely responsible for all Manufacturing activities for supply of Celgene Reverted Compounds and Celgene Reverted Products necessary for use by Celgene in a Celgene Reverted Program.

  • At such time as an Independent Program becomes a Celgene Reverted Program, Celgene shall have sole responsibility for all Regulatory Interactions with respect to the Celgene Reverted Compounds and Celgene Reverted Products Developed or Commercialized under such Celgene Reverted Program.

  • Notwithstanding the foregoing, to the extent any such expenses relate to Patent Applications solely claiming Reverted Compounds, Curis Option Compounds or the manufacture or use thereof, Wyeth shall [**] reimburse Curis for any [**] Reverted Compound or a Curis Option Compound [**] with respect to such Reverted Compound or Curis Option Compound.

  • Claimed Compounds will cease to be Claimed Compounds and will become Reverted Compounds upon Astellas’s termination of Development of the applicable Development Compounds or Backup Compounds such that there is no longer any Collaboration Patent Right that claims both such Claimed Compound and any Development Compound or Backup Compound then being Developed by Astellas.

  • When bioburden count has deviated from the acceptance criteria in moist-heat sterilization, the count should be assessed by reviewing results of sterilization resistance test together to confirm if the count satisfies the SAL of 10-6 (e.g. log [bioburden count] + 6 < sterilization time/D value).

  • In addition, Infinity shall use reasonable efforts to transition to Intellikine, upon Intellikine’s request and at Intellikine’s expense, any arrangement with any contractor from which Infinity had arranged to obtain supplies of Reverted Compounds or Reverted Products, to the extent permitted under any such agreement with such contractor.

  • Subject to Section 2.7 below, Wyeth hereby grants to Curis an irrevocable, exclusive sublicense under that Curis Technology licensed to Wyeth under Section 2.1 above for Curis to develop, make, have made, offer for sale, sell and have sold Reverted Compounds for use in the Curis Field.

Related to Reverted Compounds

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Compounds means any or all of the following chemicals, as the context requires:

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • GSK has the meaning set forth in the preamble.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Exempt compound means the same as defined in Rule 2.

  • Product Technology means the Product Know-How and Product Patents.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Biosimilar Product means, with respect to a Licensed Product and on a country-by-country basis, a product that [***].

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Licensed Product means a product or part of a product in the Licensed Field of Use: (A) the making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent; or (B) which is made with, uses or incorporates any Technology.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Commercializing means to engage in Commercialization and “Commercialized” has a corresponding meaning.

  • Joint Patent Rights means Patent Rights that contain one or more claims that cover Joint Technology.

  • Licensed Products means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  • Program Patent Rights means any Patent Rights that contain one or more claims that cover Program Inventions.